ストックスクリーナーアプリを入手
23.37
2.68%
0.61
アフターアワーズ：
23.37
前日終値:
$22.76
開ける：
$23.06
24時間の取引高:
1.55M
Relative Volume:
1.27
時価総額：
$3.03B
収益：
$460.48M
当期純損益:
$142.80M
株価収益率:
19.81
EPS:
1.18
ネットキャッシュフロー:
$221.79M
1週間 パフォーマンス:
-5.92%
1か月 パフォーマンス:
+2.77%
6か月 パフォーマンス:
-2.34%
1年 パフォーマンス:
+49.33%
1日の値動き範囲:
$22.89
$23.70
1週間の範囲:
$20.80
$24.83
52週間の値動き範囲:
$14.75
$26.16
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
名前
Catalyst Pharmaceuticals Inc
セクター
電話
(305) 529-2522
住所
355 ALHAMBRA CIRCLE, CORAL GABLES
CPRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CPRX
Catalyst Pharmaceuticals Inc
|
23.37 | 3.03B | 460.48M | 142.80M | 221.79M | 1.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-04 | 開始されました | Robert W. Baird | Outperform |
| 2024-11-18 | 開始されました | Stephens | Overweight |
| 2024-03-14 | 開始されました | Citigroup | Buy |
| 2024-03-07 | 開始されました | BofA Securities | Buy |
| 2023-12-21 | 開始されました | Oppenheimer | Outperform |
| 2022-08-24 | ダウングレード | ROTH Capital | Buy → Neutral |
| 2018-09-21 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-09-07 | 再開されました | Piper Jaffray | Overweight |
| 2016-10-05 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2016-04-26 | ダウングレード | Piper Jaffray | Overweight → Neutral |
| 2014-09-30 | 繰り返されました | ROTH Capital | Buy |
| 2014-09-16 | 繰り返されました | ROTH Capital | Buy |
| 2014-09-15 | 繰り返されました | H.C. Wainwright | Buy |
| 2013-10-21 | 繰り返されました | Aegis Capital | Buy |
| 2013-09-24 | 開始されました | Maxim Group | Buy |
| 2013-09-06 | 繰り返されました | Aegis Capital | Buy |
| 2013-04-18 | 開始されました | Aegis Capital | Buy |
| 2012-08-27 | アップグレード | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| 2009-10-01 | アップグレード | Merriman | Sell → Neutral |
| 2009-05-29 | ダウングレード | Hapoalim | Neutral → Underperform |
| 2009-05-29 | ダウングレード | Merriman Curhan Ford | Buy → Sell |
| 2008-12-15 | 開始されました | Merriman Curhan Ford | Buy |
| 2007-11-28 | 開始されました | Rodman & Renshaw | Mkt Outperform |
| 2007-01-31 | 開始されました | Stifel Nicolaus | Buy |
| 2007-01-05 | 開始されました | First Albany | Buy |
すべてを表示
Catalyst Pharmaceuticals Inc (CPRX) 最新ニュース
Catalyst pharmaceuticals reaffirms 2025 revenue guidance of $545M-$565M with strong FIRDAPSE and AGAMREE performance - MSN
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q1 2025 Earnings Call Transcript - Insider Monkey
Catalyst Pharmaceuticals Reports Record Q1 2025 Results - TipRanks
Catalyst Pharmaceuticals Inc (CPRX) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/Y - Zacks Investment Research
Earnings call transcript: Catalyst Pharmaceuticals Q1 2025 earnings beat fails to impress market - Investing.com
Catalyst Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Catalyst Pharmaceutical (CPRX) Q1 Earnings and Revenues Top Estimates - Yahoo Finance
Catalyst Pharmaceuticals (CPRX) Exceeds Q1 Revenue Expectations | CPRX Stock News - GuruFocus
Catalyst Pharma Reports Record Q1 2025 Financial Results - TipRanks
Earnings Flash (CPRX) Catalyst Pharmaceuticals Reports Q1 Revenue $141.4M, vs. FactSet Est of $131.5M - marketscreener.com
Catalyst Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Catalyst Pharmaceuticals Inc (CPRX) Q1 2025: Everything You Need To Know Ahead Of Earnings - GuruFocus
BlackRock, Inc. Reduces Stake in Catalyst Pharmaceuticals Inc - GuruFocus
Catalyst Pharmaceutical (CPRX) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
Catalyst Pharmaceuticals to Participate in the BofA Securities H - GuruFocus
Catalyst Pharmaceuticals to Participate in the BofA Securities Health Care Conference 2025 - The Manila Times
Is Now The Time To Put Catalyst Pharmaceuticals (NASDAQ:CPRX) On Your Watchlist? - Yahoo
Catalyst Pharmaceuticals Leadership Team to Share Rare Disease Strategy at Major BofA Healthcare Conference - Stock Titan
Catalyst Pharmaceuticals (NASDAQ:CPRX) stock performs better than its underlying earnings growth over last five years - simplywall.st
Catalyst Pharmaceuticals, Inc. (CPRX): Among Stocks with Consistent Growth to Buy Now - MSN
Press Release Distribution & PR Platform - ACCESS Newswire
Catalyst Pharmaceuticals Inc. stock rises Friday, still underperforms market - MarketWatch
Catalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025 | CPRX Stock News - GuruFocus
Catalyst Pharmaceuticals to Release First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025 - Nasdaq
Catalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025 - GlobeNewswire
BofA Adjusts Price Target on Catalyst Pharmaceuticals to $34 From $33 - marketscreener.com
Catalyst Pharmaceuticals (CPRX) Sees Price Target Boost from Bof - GuruFocus
Catalyst Pharmaceuticals (CPRX) Sees Price Target Boost from BofA to $34 | CPRX Stock News - GuruFocus
Catalyst Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Is Catalyst Pharmaceuticals, Inc. (CPRX) the Best Russell 2000 Stock to Buy According to Wall Street Analysts? - MSN
11 Best Russell 2000 Stocks to Buy According to Wall Street Analysts - Insider Monkey
Catalyst Pharmaceuticals (NasdaqCM:CPRX) Navigates Market Volatility With 3% Dip - Yahoo Finance
New Drug Submission for AGAMREE® (vamorolone) Accepted for Priority Review by Health Canada for the Treatment of Duchenne Muscular Dystrophy - BioSpace
Catalyst Says Health Canada Accepts New Drug Submission for Potential Neuromuscular Disease Treatment - marketscreener.com
Catalyst Pharmaceuticals Announces Health Canada’s - GlobeNewswire
First DMD Treatment Could Reach Canada as AGAMREE Receives Priority Review Status - Stock Titan
Lambert Eaton Myasthenic Syndrome Market 2025: Growth, - openPR.com
Why a Clutch of Pharmaceutical and Biotech Stocks Escaped the Market's Swoon on Thursday - Yahoo Finance
What Makes Catalyst Pharmaceuticals (CPRX) an Investment Choice? - MSN
Prudential Financial Inc. Buys 128,525 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch
Catalyst Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
Cornercap Investment Counsel Inc. Takes Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst (CPRX) Up 14.7% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Jim Cramer on Catalyst Pharmaceuticals (CPRX): ‘That’s My Kind of Stock!’ - MSN
Catalyst Pharmaceuticals Inc (CPRX) 財務データ
収益
当期純利益
現金流量
EPS
0.84%
0.15%
大文字化:
|
ボリューム (24 時間):